BeiGene's PD-1 scores PhI­II win in esophageal can­cer — a 'key in­di­ca­tion' tapped by No­var­tis in $650M deal

Days af­ter bring­ing BeiGene’s PD-1 in­to its port­fo­lio, No­var­tis is adding a feath­er to its tislelizum­ab cap.

BeiGene re­port­ed that in the sec­ond-line set­ting, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER